Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial
The Lancet Jul 17, 2019
Gerstein HC, et al. - In individuals with type 2 diabetes with and without previous cardiovascular disease and a wide range of glycemic control, researchers sought to examine how major adverse cardiovascular events are affected when the glucagon-like peptide-1 receptor agonist dulaglutide is added to their existing antihyperglycemic regimens. This multicenter, randomized, double-blind, placebo-controlled trial was conducted at 371 sites in 24 countries and included men and women aged at least 50 years with type 2 diabetes who had either a previous cardiovascular event or cardiovascular risk factors. They randomly assigned (1:1) 9,901 participants (mean age 66.2 years; median HbA 1c 7.2%; 4,589 [46.3%] women) to receive dulaglutide (n=4,949) or placebo (n=4,952). Outcomes suggest that consideration could be given to dulaglutide for managing glycemic control in middle-aged and older people with type 2 diabetes with either previous cardiovascular disease or cardiovascular risk factors.
Sign-up to continue reading. It is free & takes less than 2 mins
45 lakhs+ doctors trust M3 globally
Free & unlimited access to original articles and quizzes
Secure: we never sell your data